Deciphera Pharmaceuticals DCPH 深 沪
等待开盘 04-01 09:30:00 美东时间
25.59
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 25.59
- 总市值 20.68亿
- 52周最高 25.61
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 9.90
- 委 比 0.00%
- 总股本 8080.01万
- 历史最高 71.11
- 量 比 0
- 振 幅 0.00%
- 历史最低 6.51
- 每 手 1
- 风险率 4.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ONO Pharmaceutical Introduces Long-Term Incentive Stock Plan for Deciphera Employees
ONO Pharmaceutical Introduces Long-Term Incentive Stock Plan for Deciphera Employees ONO Pharmaceutical said it will introduce a long-term incentive stock plan for employees of its U.S. subsidiary, Deciphera Pharmaceuticals, using an Employee Stock Ownership Plan trust structure. Ono plans to transf
03-05 11:01
ONO Pharmaceutical Launches Stock Grant ESOP Trust Incentive Plan for Deciphera Employees
ONO Pharmaceutical Launches Stock Grant ESOP Trust Incentive Plan for Deciphera Employees ONO Pharmaceutical Co. Ltd. approved a long-term incentive stock compensation plan, a Stock Grant ESOP Trust, for employees of its U.S. subsidiary Deciphera Pharmaceuticals. To fund the plan, Ono will dispose o
03-05 11:01
BRIEF-Deciphera Pharmaceuticals Announces U.S. Food And Drug Administration Acceptance For Filing Of Drug Application For Tirabrutinib
BRIEF-Deciphera Pharmaceuticals Announces U.S. Food And Drug Administration Acceptance For Filing Of Drug Application For Tirabrutinib Feb 17 (Reuters) - DECIPHERA PHARMACEUTICALS ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION FOR TIRABRUTINIB IN PATIENTS W
02-17 20:29
Nuvalent Appoints Ron Squarer to Board of Directors
Nuvalent Inc. has announced the appointment of Ron Squarer to its Board of Directors. Squarer brings over 30 years of experience in oncology drug development and commercialization, having previously s...
2025-12-11 05:05
J.P. Morgan Life Sciences Private Capital Welcomes Dashyant Dhanak, Ph.D. as Venture Partner
NEW YORK, May 19, 2025 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital, the life sciences venture and growth equity arm within J.P. Morgan Asset Management, today announced the app...
2025-05-19 22:00
Ono Pharmaceutical completes tender offer for Deciphera
Ono Pharmaceutical has successfully completed its $2.4B tender offer for Deciphera Pharmaceuticals (NASDAQ:DCPH). As a result of the transaction, Deciphera is now a wholly owned subsidiary of Ono, wit...
2024-06-11 22:22
Deciphera Pharmaceuticals: Significant Post-Merger Corporate Changes
An update from Deciphera Pharmaceuticals (DCPH) is now available. Following the...
2024-06-11 21:59
Kuehn Law Encourages HIBB, CRGY, DCPH, and HCP Investors to Contact Law Firm
NEW YORK, June 3, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek...
2024-06-04 01:07
快讯 | Deciphera Pharmaceuticals预计在2024年第二季度提交新药申请并在2024年第三季度提交营销授权申请。
Deciphera Pharmaceuticals预计在2024年第二季度提交新药申请并在2024年第三季度提交营销授权申请。
2024-06-03 06:02
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 74% Share Price Surge Not Quite Adding Up
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shareholders would be excited to ...
2024-05-24 20:51
